Examining the biological features of early breast cancer in Pakistani women
Official title: Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population
Run by Liaquat University of Medical & Health Sciences · NCT06830590 · Data updated 2026-11-12
This study looks at the unique biological features of early breast cancer in Pakistani women to better understand the disease.
Quick facts
| Study type | Observational |
|---|---|
| Sex | Women only |
| Enrollment | 300 (estimated) |
| Sponsor | Liaquat University of Medical & Health Sciences Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Jamshoro) |
| Status | Recruiting |
| Started | February 1, 2016 |
| Main results expected | December 30, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | August 13, 2025 |
| Trial ID | NCT06830590 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are women diagnosed with early operable primary breast cancer who have not received any neoadjuvant therapy.
✕Probably not a fit
Patients who have undergone pre-operative chemotherapy or radiotherapy will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on the molecular characterization of early operable primary breast cancer specifically within the Pakistani population. It aims to analyze the biological characteristics of breast cancer using immunohistochemistry (IHC) techniques. The study will involve women who have a confirmed diagnosis of breast cancer and have not undergone any pre-operative chemotherapy or radiotherapy, ensuring the collection of high-quality tumor samples for analysis.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of breast cancer biology in Pakistani women, leading to improved treatment strategies.
How similar studies have gone: While similar studies have been conducted in other populations, this specific focus on the Pakistani population represents a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women with confirmed diagnosis of breast cancer without history of taking neoadjuvant therapy Good quality tumour samples available for IHC Exclusion Criteria: * patients received pre-operative chemotherapy or radiotherapy
Where it's running
-
Binafsha M Syed
Jamshoro, Pakistan Recruiting
Study contacts
- Principal investigator: Binafsha Manzoor M Syed, MBBS, PhD — Liaquat University of Medical & Health Sciences, Jamshoro
- Study coordinator: Binafsha Manzoor M Syed, MBBS, PhD
- Email: Binafsha.syed@lumhs.edu.pk
- Phone: +923332749201
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gyrotonic exercise for elders with breast cancer and Behcet disease
We’re testing whether a gyrotonic exercise program helps older people who have both Behcet disease and breast cancer.
-
PECS II vs SPSIP nerve blocks for pain after mastectomy
This study tests whether two ultrasound-guided nerve blocks (PECS II and SPSIP) differ in how much opioid patients need after mastectomy.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
Compare a new endoscopy-assisted breast-conserving surgery with the usual approach
This study tests whether a new endoscopy-assisted breast-conserving technique can provide similar or better cosmetic outcomes and safety compared with conventional breast-conserving surgery in women with early breast cancer who want to preserve their breast.
-
Different skin care approaches to prevent skin reactions after mastectomy radiation
This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.
-
3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy
This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.